The physiological roles of amyloid-β peptide hint at new ways to treat Alzheimer's disease

Frontiers in Aging Neuroscience

Volumn 10, Issue APR, 2018, Pages

  Brothers, Holly M ^a   Gosztyla, Maya L ^a   Robinson, Stephen R ^b  

^a OHIO STATE UNIVERSITY   (United States)

^b RMIT UNIVERSITY   (Australia)

Author keywords

Antimicrobial; ARIA; Cancer; Cerebrovascular; Immune system; Infection; Seizure; Traumatic injury

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; APOLIPOPROTEIN E4; COLLAGEN TYPE 4; FIBRINOGEN; HEMIN; HEMOGLOBIN; IMMUNOGLOBULIN G; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; SECRETASE; SERUM ALBUMIN; TAU PROTEIN; THROMBIN; VON WILLEBRAND FACTOR;

ALZHEIMER DISEASE; AMINO ACID SEQUENCE; BLOOD BRAIN BARRIER; HUMAN; LONG TERM POTENTIATION; MEMORY CONSOLIDATION; NERVE CELL PLASTICITY; NEUROPATHOLOGY; PROTEIN BINDING; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION; PROTEIN SYNTHESIS; REVIEW;

EID: 85046347640     PISSN: None     EISSN: 16634365     Source Type: Journal    
DOI: 10.3389/fnagi.2018.00118     Document Type: Review

References (231)

1. Abramowski, D., Wiederhold, K.-H., Furrer, U., Jaton, A.-L., Neuenschwander, A., Runser, M.-J., et al. (2008). Dynamics of Abeta turnover and deposition in different beta-amyloid precursor protein transgenic mouse models following gamma-secretase inhibition. J. Pharmacol. Exp. Ther. 327, 411-424. doi: 10.1124/jpet.108.140327
2. Abu Hamdeh, S., Waara, E. R., Möller, C., Söderberg, L., Basun, H., Alafuzoff, I., et al. (2017). Rapid amyloid-β oligomer and protofibril accumulation in traumatic brain injury. Brain Pathol. doi: 10.1111/bpa.12532. [Epub ahead of print]
3. Acosta, S. A., Tajiri, N., Sanberg, P. R., Kaneko, Y., and Borlongan, C. V. (2017). Increased amyloid precursor protein and tau expression manifests as key secondary cell death in chronic traumatic brain injury. J. Cell. Physiol. 232, 665-677. doi: 10.1002/jcp.25629
4. Aisen, P. S., Gauthier, S., Vellas, B., Briand, R., Saumier, D., Laurin, J., et al. (2007). Alzhemed: a potential treatment for Alzheimer's disease. Curr. Alzheimer Res. 4, 473-478. doi: 10.2174/156720507781788882
5. Aisen, P. S., Saumier, D., Briand, R., Laurin, J., Gervais, F., Tremblay, P., et al. (2006). A phase II study targeting amyloid-beta with 3APS in mild-to-moderate Alzheimer disease. Neurology 67, 1757-1763. doi: 10.1212/01.wnl.0000244346.08950.64
6. Alonso, R., Pisa, D., Marina, A. I., Morato, E., Rábano, A., and Carrasco, L. (2014). Fungal infection in patients with Alzheimer's disease. J. Alzheimers Dis. 41, 301-311. doi: 10.3233/JAD-132681
7. Alonso, R., Pisa, D., Rábano, A., Rodal, I., and Carrasco, L. (2015). Cerebrospinal fluid from Alzheimer's disease patients contains fungal proteins and DNA. J. Alzheimers Dis. 47, 873-876. doi: 10.3233/JAD-150382
8. AlzForum (2009). Drug Brief-Adverse Events Prompt Dose Drop in Elan Trial. Available online at: http://www.alzforum.org/news/research-news/drug-brief-adverse-events-prompt-dose-drop-elan-trial
9. AlzForum (2012a). Bapineuzumab Phase 3: Target Engagement, But No Benefit. Available online at: http://www.alzforum.org/news/conference-coverage/bapineuzumab-phase-3-target-engagement-no-benefit
10. AlzForum (2012b). Clinical Trials of Intravenous Bapineuzumab Halted. Available online at: http://www.alzforum.org/news/research-news/clinical-trials-intravenous-bapineuzumab-halted
11. AlzForum (2013). Anti-Amyloid Results Show Modest Benefits, Mild Side Effects. Available online at: http://www.alzforum.org/news/conference-coverage/anti-amyloid-results-show-modest-benefits-mild-side-effects
12. AlzForum (2014a). Denied Breakthroughs, Researchers Keep Hunting New Therapies. Available online at: http://www.alzforum.org/news/conference-coverage/denied-breakthroughs-researchers-keep-hunting-new-therapies
13. AlzForum (2014b). In Surprise, Placebo, not Aβ Vaccine, Said to Slow Alzheimer's. Available online at: http://www.alzforum.org/news/research-news/surprise-placebo-not-av-vaccine-said-slow-alzheimers
14. AlzForum (n.d.-a). Aducanumab. Available online at: http://www.alzforum.org/therapeutics/aducanumab
15. AlzForum (n.d.-b). Affitope AD02. Available online at: http://www.alzforum.org/therapeutics/affitope-ad02
16. AlzForum (n.d.-c). AN-1792. Available online at: http://www.alzforum.org/therapeutics/1792
17. AlzForum (n.d.-d). Avagacestat. Available online at: http://www.alzforum.org/therapeutics/avagacestat
18. AlzForum (n.d.-e). Bapineuzumab. Available online at: http://www.alzforum.org/therapeutics/bapineuzumab
19. AlzForum (n.d.-f). BI 1181181. Available online at: http://www.alzforum.org/therapeutics/bi-1181181
20. AlzForum (n.d.-g). CAD106. Available online at: http://www.alzforum.org/therapeutics/cad106
21. AlzForum (n.d.-h). E2609. Available online at: http://www.alzforum.org/therapeutics/e2609
22. AlzForum (n.d.-i). ELND005. Available online at: http://www.alzforum.org/therapeutics/elnd005
23. AlzForum (n.d.-j). Gantenerumab. Available online at: http://www.alzforum.org/therapeutics/gantenerumab
24. AlzForum (n.d.-k). LY2886721. Available online at: http://www.alzforum.org/therapeutics/ly2886721
25. AlzForum (n.d.-l). RG7129. Available online at: http://www.alzforum.org/therapeutics/rg7129
26. AlzForum (n.d.-m). Semagacestat. Available online at: http://www.alzforum.org/therapeutics/semagacestat
27. Angel, T. E., Jacobs, J. M., Smith, R. P., Pasternack, M. S., Elias, S., Gritsenko, M. A., et al. (2012). Cerebrospinal fluid proteome of patients with acute Lyme disease. J. Proteome Res. 11, 4814-4822. doi: 10.1021/pr300577p
28. Arroyo Mühr, L. S., Hultin, E., Bzhalava, D., Eklund, C., Lagheden, C., Ekström, J., et al. (2015). Human papillomavirus type 197 is commonly present in skin tumors. Int. J. Cancer. 136, 2546-2555. doi: 10.1002/ijc.29325
29. Ashby, E. L., Miners, J. S., Kehoe, P. G., and Love, S. (2016). Effects of hypertension and anti-hypertensive treatment on amyloid-β (Aβ) plaque load and Aβ-synthesizing and Aβ-degrading enzymes in frontal cortex. J. Alzheimers Dis. 50, 1191-1203. doi: 10.3233/JAD-150831
30. Atwood, C. S., Bowen, R. L., Smith, M. A., and Perry, G. (2003). Cerebrovascular requirement for sealant, anti-coagulant and remodeling molecules that allow for the maintenance of vascular integrity and blood supply. Brain Res. Brain Res. Rev. 43, 164-178. doi: 10.1016/S0165-0173(03)00206-6
31. Bagnato, S., Andriolo, M., Boccagni, C., and Galardi, G. (2017). Prolonged changes in amyloid-β metabolism after a severe traumatic brain injury. Neuroreport 28, 250-252. doi: 10.1097/WNR.0000000000000748
32. Balin, B. J., Gérard, H. C., Arking, E. J., Appelt, D. M., Branigan, P. J., Abrams, J. T., et al. (1998). Identification and localization of Chlamydia pneumoniae in the Alzheimer's brain. Med. Microbiol. Immunol. 187, 23-42. doi: 10.1007/s004300050071
33. Balin, B. J., Little, C. S., Hammond, C. J., Appelt, D. M., Whittum-Hudson, J. A., Gérard, H. C., et al. (2008). Chlamydophila pneumoniae and the etiology of late-onset Alzheimer's disease. J. Alzheimers Dis. 13, 371-380. doi: 10.3233/JAD-2008-13403
34. Ball, M. J. (1982). Limbic predilection in Alzheimer dementia: is reactivated herpesvirus involved? Can. J. Neurol. Sci. 9, 303-306
35. Ball, M. J., Lukiw, W. J., Kammerman, E. M., and Hill, J. M. (2013). Intracerebral propagation of Alzheimer's disease: strengthening evidence of a herpes simplex virus etiology. Alzheimers Dement. 9, 169-175. doi: 10.1016/j.jalz.2012.07.005
36. Bateman, R. J., Siemers, E. R., Mawuenyega, K. G., Wen, G., Browning, K. R., Sigurdson, W. C., et al. (2009). A gamma-secretase inhibitor decreases amyloid-beta production in the central nervous system. Ann. Neurol. 66, 48-54. doi: 10.1002/ana.21623
37. Batton, C. I., O'Dowd, B. S., Noone, D. F., Kril, J., and Robinson, S. R. (1997). Ferritin-rich microglia are concentrated within β-amyloid plaques. Alzheimers Res. 3, 23-28
38. Bird, S. M., Sohrabi, H. R., Sutton, T. A., Weinborn, M., Rainey-Smith, S. R., Brown, B., et al. (2016). Cerebral amyloid-β accumulation and deposition following traumatic brain injury-A narrative review and meta-analysis of animal studies. Neurosci. Biobehav. Rev. 64, 215-228. doi: 10.1016/j.neubiorev.2016.01.004
39. Bishop, G. M., and Robinson, S. R. (2002). The amyloid hypothesis: let sleeping dogmas lie? Neurobiol. Aging 23, 1101-1105. doi: 10.1016/S0197-4580(02)00050-7
40. Bishop, G. M., and Robinson, S. R. (2004a). Physiological roles of amyloid-beta and implications for its removal in Alzheimer's disease. Drugs Aging 21, 621-630. doi: 10.2165/00002512-200421100-00001
41. Bishop, G. M., and Robinson, S. R. (2004b). The amyloid paradox: amyloid-beta-metal complexes can be neurotoxic and neuroprotective. Brain Pathol. 14, 448-452. doi: 10.1111/j.1750-3639.2004.tb00089.x
42. Bitel, C. L., Kasinathan, C., Kaswala, R. H., Klein, W. L., and Frederikse, P. H. (2012). Amyloid-β and tau pathology of Alzheimer's disease induced by diabetes in a rabbit animal model. J. Alzheimers Dis. 32, 291-305. doi: 10.3233/JAD-2012-120571
43. Black, R. S., Sperling, R. A., Safirstein, B., Motter, R. N., Pallay, A., Nichols, A., et al. (2010). A single ascending dose study of bapineuzumab in patients with Alzheimer disease. Alzheimer Dis. Assoc. Disord. 24, 198-203. doi: 10.1097/WAD.0b013e3181c53b00
44. Blasko, I., Beer, R., Bigl, M., Apelt, J., Franz, G., Rudzki, D., et al. (2004). Experimental traumatic brain injury in rats stimulates the expression, production and activity of Alzheimer's disease beta-secretase (BACE-1). J. Neural Trans. 111, 523-536. doi: 10.1007/s00702-003-0095-6
45. Blockx, I., Einstein, S., Guns, P. J., Van Audekerke, J., Guglielmetti, C., Zago, W., et al. (2016). Monitoring blood-brain barrier integrity following amyloid-beta immunotherapy using gadolinium-enhanced MRI in a PDAPP mouse model. J. Alzheimers Dis. 54, 723-735. doi: 10.3233/JAD-160023
46. Boche, D., Donald, J., Love, S., Harris, S., Neal, J. W., Holmes, C., et al. (2010). Reduction of aggregated Tau in neuronal processes but not in the cell bodies after Abeta42 immunisation in Alzheimer's disease. Acta Neuropathol. 120, 13-20. doi: 10.1007/s00401-010-0705-y
47. Boelen, E., Stassen, F. R., van der Ven, A. J., Lemmens, M. A., Steinbusch, H. P., Bruggeman, C. A., et al. (2007). Detection of amyloid beta aggregates in the brain of BALB/c mice after Chlamydia pneumoniae infection. Acta Neuropathol. 114, 255-261. doi: 10.1007/s00401-007-0252-3
48. Bourgade, K., Dupuis, G., Frost, E. H., and Fülöp, T. S. (2016a). Anti-viral properties of amyloid-β peptides. J. Alzheimers Dis. 54, 859-878. doi: 10.3233/JAD-160517
49. Bourgade, K., Garneau, H., Giroux, G., Le Page, A. Y., Bocti, C., Dupuis, G., et al. (2015). β-Amyloid peptides display protective activity against the human Alzheimer's disease-associated herpes simplex virus-1. Biogerontology 16, 85-98. doi: 10.1007/s10522-014-9538-8
50. Bourgade, K., Le Page, A., Bocti, C., Witkowski, J. M., Dupuis, G., Frost, E. H., et al. (2016b). Protective effect of amyloid-β peptides against herpes simplex virus-1 infection in a neuronal cell culture model. J. Alzheimers Dis. 50, 1227-1241. doi: 10.3233/JAD-150652
51. Bowles, E. J. A., Walker, R. L., Anderson, M. L., Dublin, S., Crane, P. K., and Larson, E. B. (2017). Risk of Alzheimer's disease or dementia following a cancer diagnosis. PLoS ONE 12:e0179857. doi: 10.1371/journal.pone.0179857
52. Brody, D. L., Magnoni, S., Schwetye, K. E., Spinner, M. L., Esparza, T. J., Stocchetti, N., et al. (2008). Amyloid-beta dynamics correlate with neurological status in the injured human brain. Science 321, 1221-1224. doi: 10.1126/science.1161591
53. Bueche, C. Z., Hawkes, C., Garz, C., Vielhaber, S., Attems, J., Knight, R. T., et al. (2014). Hypertension drives parenchymal β-amyloid accumulation in the brain parenchyma. Ann. Clin. Transl. Neurol. 1, 124-129. doi: 10.1002/acn3.27
54. Buhimschi, I. A., Nayeri, U. A., Zhao, G., Shook, L. L., Pensalfini, A., Funai, E. F., et al. (2014). Protein misfolding, congophilia, oligomerization, and defective amyloid processing in preeclampsia. Sci. Transl. Med. 6:245ra292. doi: 10.1126/scitranslmed.3008808
55. Busche, M. A., Grienberger, C., Keskin, A. D., Song, B., Neumann, U., Staufenbiel, M., et al. (2015). Decreased amyloid-β and increased neuronal hyperactivity by immunotherapy in Alzheimer's models. Nat. Neurosci. 18, 1725-1727. doi: 10.1038/nn.4163
56. Carnevale, D., Perrotta, M., Lembo, G., and Trimarco, B. (2016). Pathophysiological links among hypertension and Alzheimer's disease. High Blood Press. Cardiovasc. Prev. 23, 3-7. doi: 10.1007/s40292-015-0108-1
57. Catalá-López, F., Suárez-Pinilla, M., Suárez-Pinilla, P., Valderas, J. M., Gómez-Beneyto, M., Martinez, S., et al. (2014). Inverse and direct cancer comorbidity in people with central nervous system disorders: a meta-analysis of cancer incidence in 577, 013 participants of 50 observational studies. Psychother. Psychosom. 83, 89-105. doi: 10.1159/000356498
58. Charidimou, A., Martinez-Ramirez, S., Shoamanesh, A., Oliveira-Filho, J., Frosch, M., Vashkevich, A., et al. (2015). Cerebral amyloid angiopathy with and without hemorrhage: evidence for different disease phenotypes. Neurology 84, 1206-1212. doi: 10.1212/WNL.0000000000001398
59. Chen, X. H., Johnson, V. E., Uryu, K., Trojanowski, J. Q., and Smith, D. H. (2009). A lack of amyloid beta plaques despite persistent accumulation of amyloid beta in axons of long-term survivors of traumatic brain injury. Brain Pathol. 19, 214-223. doi: 10.1111/j.1750-3639.2008.00176.x
60. Chou, C. H., Lee, J. T., Lin, C. C., Sung, Y. F., Muo, C. H., Yang, F. C., et al. (2017). Septicemia is associated with increased risk for dementia: a population-based longitudinal study. Oncotarget 8, 84300-84308. doi: 10.18632/oncotarget.20899
61. Chuang, J.-Y., Lee, C.-W., Shih, Y.-H., Yang, T., Yu, L., and Kuo, Y.-M. (2012). Interactions between amyloid-β and hemoglobin: implications for amyloid plaque formation in Alzheimer's disease. PLoS ONE 7:e33120. doi: 10.1371/journal.pone.0033120
62. Cirrito, J. R., Yamada, K. A., Finn, M. B., Sloviter, R. S., Bales, K. R., May, P. C., et al. (2005). Synaptic activity regulates interstitial fluid amyloid-beta levels. Neuron 48, 913-922. doi: 10.1016/j.neuron.2005.10.028
63. Clarke, J., Thornell, A., Corbett, D., Soininen, H., Hiltunen, M., and Jolkkonen, J. (2007). Overexpression of APP provides neuroprotection in the absence of functional benefit following middle cerebral artery occlusion in rats. Eur. J. Neurosci. 26, 1845-1852. doi: 10.1111/j.1460-9568.2007.05807.x
64. Coric, V., Salloway, S., van Dyck, C. H., Dubois, B., Andreasen, N., Brody, M., et al. (2015). Targeting prodromal Alzheimer disease with avagacestat: a randomized clinical trial. JAMA Neurol. 72, 1324-1333. doi: 10.1001/jamaneurol.2015.0607
65. Coric, V., van Dyck, C. H., Salloway, S., Andreasen, N., Brody, M., Richter, R. W., et al. (2012). Safety and tolerability of the γ-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease. Arch. Neurol. 69, 1430-1440. doi: 10.1001/archneurol.2012.2194
66. Cullen, K. M., Kócsi, Z., and Stone, J. (2006). Microvascular pathology in the aging human brain: evidence that senile plaques are sites of microhaemorrhages. Neurobiol. Aging 27, 1786-1796. doi: 10.1016/j.neurobiolaging.2005.10.016
67. D'Andrea, M. R. (2014). Bursting Neurons and Fading Memories: An Alternative Hypothesis of the Pathogenesis of Alzheimer's Disease, 1st Edn. New York, NY: Academic Press
68. D'Andrea, M. R. (2016). Intracellular Consequences of Amyloid in Alzheimer's Disease. Amsterdam: Academic Press
69. Deweerdt, S. (2014). Comparative biology: naked ambition. Nature 509, S60-S61. doi: 10.1038/509S60a
70. DiFrancesco, J. C., Longoni, M., and Piazza, F. (2015). Anti-Aβ autoantibodies in amyloid related imaging abnormalities (ARIA): candidate biomarker for immunotherapy in Alzheimer's disease and cerebral amyloid angiopathy. Front. Neurol. 6:207. doi: 10.3389/fneur.2015.00207
71. Dominguez, D., Tournoy, J., Hartmann, D., Huth, T., Cryns, K., Deforce, S., et al. (2005). Phenotypic and biochemical analysis of BACE1-and BACE2-deficient mice. J. Biol. Chem. 280, 30797-30806. doi: 10.1074/jbc. M505249200
72. Doody, R. S., Raman, R., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., et al. (2013). A phase 3 trial of semagacestat for treatment of Alzheimer's disease. N. Engl. J. Med. 369, 341-350. doi: 10.1056/NEJMoa1210951
73. Dreses-Werringloer, U., Bhuiyan, M., Zhao, Y., Gérard, H. C., Whittum-Hudson, J. A., and Hudson, A. P. (2009). Initial characterization of Chlamydophila (Chlamydia) pneumoniae cultured from the late-onset Alzheimer brain. Int. J. Med. Microbiol. 299, 187-201. doi: 10.1016/j.ijmm.2008.07.002
74. Driver, J. A., Beiser, A., Au, R., Kreger, B. E., Splansky, G. L., Kurth, T., et al. (2012). Inverse association between cancer and Alzheimer's disease: results from the Framingham Heart Study. BMJ 344:e1442. doi: 10.1136/bmj.e1442
75. Dubessy, A.-L., Ursu, R., Maillet, D., Augier, A., Le Guilloux, J., Carpentier, A. F., et al. (2012). Superficial siderosis of the central nervous system: a rare cause of dementia with therapeutic consequences. Age Ageing 41, 275-277. doi: 10.1093/ageing/afr177
76. Dueholm, M. S., Otzen, D., and Nielsen, P. H. (2013). Evolutionary insight into the functional amyloids of the pseudomonads. PLoS ONE 8:e76630. doi: 10.1371/journal.pone.0076630
77. Edrey, Y. H., Medina, D. X., Gaczynska, M., Osmulski, P. A., Oddo, S., Caccamo, A., et al. (2013). Amyloid β and the longest-lived rodent: the naked mole-rat as a model for natural protection from Alzheimer's disease. Neurobiol. Aging 34, 2352-2360. doi: 10.1016/j.neurobiolaging.2013.03.032
78. Eli Lilly and Company (2008). Effect of LY450139 on the Long Term Progression of Alzheimer's Disease
79. Fedele, E., Rivera, D., Marengo, B., Pronzato, M. A., and Ricciarelli, R. (2015). Amyloid β: walking on the dark side of the moon. Mech. Ageing Dev. 152, 1-4. doi: 10.1016/j.mad.2015.09.001
80. Ferguson, B., Matyszak, M. K., Esiri, M. M., and Perry, V. H. (1997). Axonal damage in acute multiple sclerosis lesions. Brain 120(Pt 3), 393-399. doi: 10.1093/brain/120.3.393
81. Ferrer, I., Boada Rovira, M., Sánchez Guerra, M. L., Rey, M. J., and Costa-Jussá, F. (2004). Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease. Brain Pathol. 14, 11-20. doi: 10.1111/j.1750-3639.2004.tb00493.x
82. Ferrero, J., Williams, L., Stella, H., Leitermann, K., Mikulskis, A., O'Gorman, J., et al. (2016). First-in-human, double-blind, placebo-controlled, single-dose escalation study of aducanumab (BIIB037) in mild-to-moderate Alzheimer's disease. Alzheimers Dement. 2, 169-176. doi: 10.1016/j.trci.2016.06.002
83. Fleisher, A. S., Raman, R., Siemers, E. R., Becerra, L., Clark, C. M., Dean, R. A., et al. (2008). Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease. Arch. Neurol. 65, 1031-1038. doi: 10.1001/archneur.65.8.1031
84. Fox, N. C., Black, R. S., Gilman, S., Rossor, M. N., Griffith, S. G., Jenkins, L., et al. (2005). Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease. Neurology 64, 1563-1572. doi: 10.1212/01.WNL.0000159743.08996.99
85. Frain, L., Swanson, D., Cho, K., Gagnon, D., Lu, K. P., Betensky, R. A., et al. (2017). Association of cancer and Alzheimer's disease risk in a national cohort of veterans. Alzheimers Dement. 13, 1364-1370. doi: 10.1016/j.jalz.2017.04.012
86. Freedman, D. M., Wu, J., Chen, H., Kuncl, R. W., Enewold, L. R., Engels, E. A., et al. (2016). Associations between cancer and Alzheimer's disease in a U.S. Medicare population. Cancer Med. 5, 2965-2976. doi: 10.1002/cam4.850
87. Garcia-Alloza, M., Gregory, J., Kuchibhotla, K. V., Fine, S., Wei, Y., Ayata, C., et al. (2011). Cerebrovascular lesions induce transient β-amyloid deposition. Brain 134(Pt 12), 3697-3707. doi: 10.1093/brain/awr300
88. Garcia-Osta, A., and Alberini, C. M. (2009). Amyloid beta mediates memory formation. Learn. Mem. 16, 267-272. doi: 10.1101/lm.1310209
89. Garvey, M., Meehan, S., Gras, S. L., Schirra, H. J., Craik, D. J., Van der Weerden, N. L., et al. (2013). A radish seed antifungal peptide with a high amyloid fibril-forming propensity. Biochim. Biophys. Acta 1834, 1615-1623. doi: 10.1016/j.bbapap.2013.04.030
90. Gauthier, S., Aisen, P. S., Ferris, S. H., Saumier, D., Duong, A., Haine, D., et al. (2009). Effect of tramiprosate in patients with mild-to-moderate Alzheimer's disease: exploratory analyses of the MRI sub-group of the Alphase study. J. Nutr. Health Aging 13, 550-557. doi: 10.1007/s12603-009-0106-x
91. Gentile, M. T., Poulet, R., Di Pardo, A., Cifelli, G., Maffei, A., Vecchione, C., et al. (2009). Beta-amyloid deposition in brain is enhanced in mouse models of arterial hypertension. Neurobiol. Aging 30, 222-228. doi: 10.1016/j.neurobiolaging.2007.06.005
92. Gérard, H. C., Dreses-Werringloer, U., Wildt, K. S., Deka, S., Oszust, C., Balin, B. J., et al. (2006). Chlamydophila (Chlamydia) pneumoniae in the Alzheimer's brain. FEMS Immunol. Med. Microbiol. 48, 355-366. doi: 10.1111/j.1574-695X.2006.00154.x
93. Gilman, S., Koller, M., Black, R. S., Jenkins, L., Griffith, S. G., Fox, N. C., et al. (2005). Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 64, 1553-1562. doi: 10.1212/01.WNL.0000159740.16984.3C
94. Gisslén, M., Krut, J., Andreasson, U., Blennow, K., Cinque, P., Brew, B. J., et al. (2009). Amyloid and tau cerebrospinal fluid biomarkers in HIV infection. BMC Neurol. 9:63. doi: 10.1186/1471-2377-9-63
95. Gosztyla, M. L., Brothers, H. M., and Robinson, S. R. (2018). Alzheimer's amyloid-β is an antimicrobial peptide: a review of the evidence. J. Alzheimers Dis. 62, 1495-1506. doi: 10.3233/JAD-171133
96. Graham, D. I., Gentleman, S. M., Lynch, A., and Roberts, G. W. (1995). Distribution of beta-amyloid protein in the brain following severe head injury. Neuropathol. Appl. Neurobiol. 21, 27-34. doi: 10.1111/j.1365-2990.1995.tb01025.x
97. Grant, J. L., Ghosn, E. E. B., Axtell, R. C., Herges, K., Kuipers, H. F., Woodling, N. S., et al. (2012). Reversal of paralysis and reduced inflammation from peripheral administration of β-amyloid in TH1 and TH17 versions of experimental autoimmune encephalomyelitis. Sci. Transl. Med. 4:145ra105. doi: 10.1126/scitranslmed.3004145
98. Green, R. C., Schneider, L. S., Amato, D. A., Beelen, A. P., Wilcock, G., Swabb, E. A., et al. (2009). Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial. JAMA 302, 2557-2564. doi: 10.1001/jama.2009.1866
99. Hammond, C. J., Hallock, L. R., Howanski, R. J., Appelt, D. M., Little, C. S., and Balin, B. J. (2010). Immunohistological detection of Chlamydia pneumoniae in the Alzheimer's disease brain. BMC Neurosci. 11:121. doi: 10.1186/1471-2202-11-121
100. Han, M. H., Hwang, S.-I., Roy, D. B., Lundgren, D. H., Price, J. V., Ousman, S. S., et al. (2008). Proteomic analysis of active multiple sclerosis lesions reveals therapeutic targets. Nature 451, 1076-1081. doi: 10.1038/nature06559
101. Hanson, H. A., Horn, K. P., Rasmussen, K. M., Hoffman, J. M., and Smith, K. R. (2017). Is cancer protective for subsequent Alzheimer's disease risk? Evidence from the Utah population database. J. Gerontol. B Psychol. Sci. Soc. Sci. 72, 1032-1043. doi: 10.1093/geronb/gbw040
102. Ho, L., Qin, W., Pompl, P. N., Xiang, Z., Wang, J., Zhao, Z., et al. (2004). Diet-induced insulin resistance promotes amyloidosis in a transgenic mouse model of Alzheimer's disease. FASEB J. 18, 902-904. doi: 10.1096/fj.03-0978fje
103. Holmes, C., Boche, D., Wilkinson, D., Yadegarfar, G., Hopkins, V., Bayer, A., et al. (2008). Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 372, 216-223. doi: 10.1016/S0140-6736(08)61075-2
104. Hu, C., Adedokun, O., Ito, K., Raje, S., and Lu, M. (2015). Confirmatory population pharmacokinetic analysis for bapineuzumab phase 3 studies in patients with mild to moderate Alzheimer's disease. J. Clin. Pharmacol. 55, 221-229. doi: 10.1002/jcph.393
105. Hu, X., Zhou, X., He, W., Yang, J., Xiong, W., Wong, P., et al. (2010). BACE1 deficiency causes altered neuronal activity and neurodegeneration. J. Neurosci. 30, 8819-8829. doi: 10.1523/JNEUROSCI.1334-10.2010
106. Hung, V. K., Yeung, P. K., Lai, A. K., Ho, M. C., Lo, A. C., Chan, K. C., et al. (2015). Selective astrocytic endothelin-1 overexpression contributes to dementia associated with ischemic stroke by exaggerating astrocyte-derived amyloid secretion. J. Cereb. Blood Flow Metab. 35, 1687-1696 doi: 10.1038/jcbfm.2015.109
107. Ida, N., Hartmann, T., Pantel, J., Schröder, J., Zerfass, R., Förstl, H., et al. (1996). Analysis of heterogeneous A4 peptides in human cerebrospinal fluid and blood by a newly developed sensitive Western blot assay. J. Biol. Chem. 271, 22908-22914. doi: 10.1074/jbc.271.37.22908
108. Ishida, N., Ishihara, Y., Ishida, K., Tada, H., Funaki-Kato, Y., Hagiwara, M., et al. (2017). Periodontitis induced by bacterial infection exacerbates features of Alzheimer's disease in transgenic mice. NPJ Aging Mech. Dis. 3, 15. doi: 10.1038/s41514-017-0015-x
109. Itzhaki, R. F. (2014). Herpes simplex virus type 1 and Alzheimer's disease: increasing evidence for a major role of the virus. Front. Aging Neurosci. 6, 202-202. doi: 10.3389/fnagi.2014.00202
110. Itzhaki, R. F., Lathe, R., Balin, B. J., Ball, M. J., Bearer, E. L., Braak, H., et al. (2016). Microbes and Alzheimer's Disease. J. Alzheimers Dis. 51, 979-984. doi: 10.3233/JAD-160152
111. Jesse, S., Steinacker, P., Lehnert, S., Sdzuj, M., Cepek, L., Tumani, H., et al. (2010). A proteomic approach for the diagnosis of bacterial meningitis. PLoS ONE 5:e10079. doi: 10.1371/journal.pone.0010079
112. Johnson, V. E., Stewart, W., and Smith, D. H. (2010). Traumatic brain injury and amyloid-β pathology: a link to Alzheimer's disease? Nat. Rev. Neurosci. 11, 361-370. doi: 10.1038/nrn2808
113. Johnson, V. E., Stewart, W., and Smith, D. H. (2012). Widespread t and amyloid-β pathology many years after a single traumatic brain injury in humans. Brain Pathol. 22, 142-149. doi: 10.1111/j.1750-3639.2011.00513.x
114. Joseph-Mathurin, N., Dorieux, O., Trouche, S. G., Boutajangout, A., Kraska, A., Fontès, P., et al. (2013). Amyloid beta immunization worsens iron deposits in the choroid plexus and cerebral microbleeds. Neurobiol. Aging 34, 2613-2622. doi: 10.1016/j.neurobiolaging.2013.05.013
115. Kagan, B. L., Jang, H., Capone, R., Teran Arce, F., Ramachandran, S., Lal, R., et al. (2012). Antimicrobial properties of amyloid peptides. Mol. Pharm. 9, 708-717. doi: 10.1021/mp200419b
116. Kalkunte, S. S., Neubeck, S., Norris, W. E., Cheng, S.-B., Kostadinov, S., Vu Hoang, D., et al. (2013). Transthyretin is dysregulated in preeclampsia, and its native form prevents the onset of disease in a preclinical mouse model. Am. J. Pathol. 183, 1425-1436. doi: 10.1016/j.ajpath.2013.07.022
117. Kamenetz, F., Tomita, T., Hsieh, H., Seabrook, G., Borchelt, D., Iwatsubo, T., et al. (2003). APP processing and synaptic function. Neuron 37, 925-937. doi: 10.1016/S0896-6273(03)00124-7
118. Kazim, S. F., Chuang, S. C., Zhao, W., Wong, R. K., Bianchi, R., and Iqbal, K. (2017). Early-onset network hyperexcitability in presymptomatic Alzheimer's disease transgenic mice is suppressed by passive immunization with anti-human APP/Abeta antibody and by mGluR5 blockade. Front. Aging Neurosci. 9:71. doi: 10.3389/fnagi.2017.00071
119. Ketter, N., Brashear, H. R., Bogert, J., Di, J., Miaux, Y., Gass, A., et al. (2017). Central review of amyloid-related imaging abnormalities in two phase III clinical trials of bapineuzumab in mild-to-moderate Alzheimer's Disease patients. J. Alzheimers Dis. 57, 557-573. doi: 10.3233/JAD-160216
120. Koike, M. A., Lin, A. J., Pham, J., Nguyen, E., Yeh, J. J., Rahimian, R., et al. (2012). APP knockout mice experience acute mortality as the result of ischemia. PLoS ONE 7:e42665. doi: 10.1371/journal.pone.0042665
121. Kokiko-Cochran, O. N., Ransohoff, L., Veenstra, M., Lee, S., Saber, M., Sikora, M., et al. (2016). Altered neuroinflammation and behavior following traumatic brain injury in a mouse model of Alzheimer's disease. J. Neurotrauma 33, 625-640. doi: 10.1089/neu.2015.3970
122. Kokjohn, T. A., and Roher, A. E. (2009). Antibody responses, amyloid-beta peptide remnants and clinical effects of AN-1792 immunization in patients with AD in an interrupted trial. CNS Neurol. Disord. Drug Targets 8, 88-97. doi: 10.2174/187152709787847315
123. Koppensteiner, P., Trinchese, F., Fà, M., Puzzo, D., Gulisano, W., Yan, S., et al. (2016). Time-dependent reversal of synaptic plasticity induced by physiological concentrations of oligomeric Abeta42: an early index of Alzheimer's disease. Sci. Rep. 6:32553. doi: 10.1038/srep32553
124. Krut, J. J., Zetterberg, H., Blennow, K., Cinque, P., Hagberg, L., Price, R. W., et al. (2013). Cerebrospinal fluid Alzheimer's biomarker profiles in CNS infections. J. Neurol. 260, 620-626. doi: 10.1007/s00415-012-6688-y
125. Kumar, D. K. V., Choi, S. H., Washicosky, K. J., Eimer, W. A., Tucker, S., Ghofrani, J., et al. (2016). Amyloid-β peptide protects against microbial infection in mouse and worm models of Alzheimer's disease. Sci. Transl. Med. 8:340ra372. doi: 10.1126/scitranslmed.aaf1059
126. Lannfelt, L., Relkin, N. R., and Siemers, E. R. (2014). Amyloid-β-directed immunotherapy for Alzheimer's disease. J. Intern. Med. 275, 284-295. doi: 10.1111/joim.12168
127. Little, C. S., Hammond, C. J., MacIntyre, A., Balin, B. J., and Appelt, D. M. (2004). Chlamydia pneumoniae induces Alzheimer-like amyloid plaques in brains of BALB/c mice. Neurobiol. Aging 25, 419-429. doi: 10.1016/S0197-4580(03)00127-1
128. Little, C. S., Joyce, T. A., Hammond, C. J., Matta, H., Cahn, D., Appelt, D. M., et al. (2014). Detection of bacterial antigens and Alzheimer's disease-like pathology in the central nervous system of BALB/c mice following intranasal infection with a laboratory isolate of Chlamydia pneumoniae. Front. Aging Neurosci. 6, 304-304. doi: 10.3389/fnagi.2014.00304
129. Lukiw, W. J., Cui, J. G., Yuan, L. Y., Bhattacharjee, P. S., Corkern, M., Clement, C., et al. (2010). Acyclovir or Aβ42 peptides attenuate HSV-1-induced miRNA-146a levels in human primary brain cells. Neuroreport 21, 922-927. doi: 10.1097/WNR.0b013e32833da51a
130. Luna, S., Cameron, D. J., and Ethell, D. W. (2013). Amyloid-β and APP deficiencies cause severe cerebrovascular defects: important work for an old villain. PLoS ONE 8:e75052. doi: 10.1371/journal.pone.0075052
131. Ma, K., Thomason, L. A., and McLaurin, J. (2012). scyllo-Inositol, preclinical, and clinical data for Alzheimer's disease. Adv. Pharmacol. 64, 177-212. doi: 10.1016/B978-0-12-394816-8.00006-4
132. Ma, L.-L., Yu, J.-T., Wang, H.-F., Meng, X.-F., Tan, C.-C., Wang, C., et al. (2014). Association between cancer and Alzheimer's disease: systematic review and meta-analysis. J. Alzheimer's Dis. 42, 565-573. doi: 10.3233/JAD-140168
133. Macfarlane, D. P., Nicoll, J. A., Smith, C., and Graham, D. I. (1999). APOE epsilon4 allele and amyloid beta-protein deposition in long term survivors of head injury. Neuroreport 10, 3945-3948. doi: 10.1097/00001756-199912160-00040
134. Magnoni, S., Esparza, T. J., Conte, V., Carbonara, M., Carrabba, G., Holtzman, D. M., et al. (2012). Tau elevations in the brain extracellular space correlate with reduced amyloid-β levels and predict adverse clinical outcomes after severe traumatic brain injury. Brain 135(Pt 4), 1268-1280. doi: 10.1093/brain/awr286
135. Malek-Ahmadi, M., Beach, T., Obradov, A., Sue, L., Belden, C., Davis, K., et al. (2013). Increased Alzheimer's disease neuropathology is associated with type 2 diabetes and ApoE e.4 carrier status. Curr. Alzheimer Res. 10, 654-659. doi: 10.2174/15672050113109990006
136. Mannix, R. C., Zhang, J., Berglass, J., Qui, J., and Whalen, M. J. (2013). Beneficial effect of amyloid beta after controlled cortical impact. Brain Injury 27, 743-748. doi: 10.3109/02699052.2013.771797
137. Mannix, R. C., Zhang, J., Park, J., Lee, C., and Whalen, M. J. (2011a). Detrimental effect of genetic inhibition of B-site APP-cleaving enzyme 1 on functional outcome after controlled cortical impact in young adult mice. J. Neurotrauma 28, 1855-1861. doi: 10.1089/neu.2011.1759
138. Mannix, R. C., Zhang, J., Park, J., Zhang, X., Bilal, K., Walker, K., et al. (2011b). Age-dependent effect of apolipoprotein E4 on functional outcome after controlled cortical impact in mice. J. Cereb. Blood Flow Metab. 31, 351-361. doi: 10.1038/jcbfm.2010.99
139. Masliah, E., Hansen, L., Adame, A., Crews, L., Bard, F., Lee, C., et al. (2005). Abeta vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease. Neurology 64, 129-131. doi: 10.1212/01.WNL.0000148590.39911.DF
140. Masters, C. L., and Selkoe, D. J. (2012). Biochemistry of amyloid β-protein and amyloid deposits in Alzheimer disease. Cold Spring Harb. Perspect. Med. 2:a006262. doi: 10.1101/cshperspect.a006262
141. Mattsson, N., Bremell, D., Anckarsäter, R., Blennow, K., Anckarsäter, H., Zetterberg, H., et al. (2010). Neuroinflammation in Lyme neuroborreliosis affects amyloid metabolism. BMC Neurol. 10:51. doi: 10.1186/1471-2377-10-51
142. Mauri, M., Sinforiani, E., Bono, G., Cittadella, R., Quattrone, A., Boller, F., et al. (2006). Interaction between apolipoprotein epsilon 4 and traumatic brain injury in patients with Alzheimer's disease and mild cognitive impairment. Funct. Neurol. 21, 223-228
143. McKenzie, K. J., McLellan, D. R., Gentleman, S. M., Maxwell, W. L., Gennarelli, T. A., and Graham, D. I. (1996). Is beta-APP a marker of axonal damage in short-surviving head injury? Acta Neuropathol. 92, 608-613. doi: 10.1007/s004010050568
144. Miklossy, J. (2015). Historic evidence to support a causal relationship between spirochetal infections and Alzheimer's disease. Front. Aging Neurosci. 7, 46-46. doi: 10.3389/fnagi.2015.00046
145. Miklossy, J. (2016). Bacterial Amyloid and DNA are important constituents of senile plaques: further evidence of the spirochetal and biofilm nature of senile plaques. J. Alzheimer's Dis. 53, 1459-1473. doi: 10.3233/JAD-160451
146. Mo, J.-A., Lim, J.-H., Sul, A.-R., Lee, M., Youn, Y. C., and Kim, H.-J. (2015). Cerebrospinal fluid β-amyloid1-42 levels in the differential diagnosis of Alzheimer's disease-systematic review and meta-analysis. PLoS ONE 10:e0116802. doi: 10.1371/journal.pone.0116802
147. Montagne, A., Barnes, S. R., Sweeney, M. D., Halliday, M. R., Sagare, A. P., Zhao, Z., et al. (2015). Blood-brain barrier breakdown in the aging human hippocampus. Neuron 85, 296-302. doi: 10.1016/j.neuron.2014.12.032
148. Morley, J. E., and Farr, S. A. (2014). The role of amyloid-beta in the regulation of memory. Biochem. Pharmacol. 88, 479-485. doi: 10.1016/j.bcp.2013.12.018
149. Morley, J. E., Farr, S. A., Banks, W. A., Johnson, S. N., Yamada, K. A., and Xu, L. (2010). A physiological role for amyloid-beta protein:enhancement of learning and memory. J. Alzheimers. Dis. 19, 441-449. doi: 10.3233/JAD-2010-1230
150. Nicoll, J. A., Wilkinson, D., Holmes, C., Steart, P., Markham, H., and Weller, R. O. (2003). Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat. Med. 9, 448-452. doi: 10.1038/nm840
151. Nicoll, J. A., Roberts, G. W., and Graham, D. I. (1995). Apolipoprotein E epsilon 4 allele is associated with deposition of amyloid beta-protein following head injury. Nat. Med. 1, 135-137. doi: 10.1038/nm0295-135
152. Orgogozo, J. M., Gilman, S., Dartigues, J. F., Laurent, B., Puel, M., Kirby, L. C., et al. (2003). Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 61, 46-54. doi: 10.1212/01.WNL.0000073623.84147.A8
153. Ostrowitzki, S., Deptula, D., Thurfjell, L., Barkhof, F., Bohrmann, B., Brooks, D. J., et al. (2012). Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab. Arch. Neurol. 69, 198-207. doi: 10.1001/archneurol.2011.1538
154. Ostrowitzki, S., Lasser, R. A., Dorflinger, E., Scheltens, P., Barkhof, F., Nikolcheva, T., et al. (2017). A phase III randomized trial of gantenerumab in prodromal Alzheimer's disease. Alzheimers. Res. Ther. 9:95. doi: 10.1186/s13195-017-0318-y
155. Oyama, R., Yamamoto, H., and Titani, K. (2000). Glutamine synthetase, hemoglobin alpha-chain, and macrophage migration inhibitory factor binding to amyloid β-protein: their identification in rat brain by a novel affinity chromatography and in Alzheimer's disease brain by immunoprecipitation. Biochim. Biophys. Acta 1479, 91-102. doi: 10.1016/S0167-4838(00)00057-1
156. Pajoohesh-Ganji, A., Burns, M. P., Pal-Ghosh, S., Tadvalkar, G., Hokenbury, N. G., Stepp, M. A., et al. (2014). Inhibition of amyloid precursor protein secretases reduces recovery after spinal cord injury. Brain Res. 1560, 73-82. doi: 10.1016/j.brainres.2014.02.049
157. Paris, D., Ganey, N., Banasiak, M., Laporte, V., Patel, N., Mullan, M., et al. (2010). Impaired orthotopic glioma growth and vascularization in transgenic mouse models of Alzheimer's disease. J. Neurosci. 30, 11251-11258. doi: 10.1523/JNEUROSCI.2586-10.2010
158. Paris, D., Quadros, A., Patel, N., DelleDonne, A., Humphrey, J., and Mullan, M. (2005). Inhibition of angiogenesis and tumor growth by beta and gamma-secretase inhibitors. Eur. J. Pharmacol. 514, 1-15. doi: 10.1016/j.ejphar.2005.02.050
159. Paris, D., Townsend, K., Quadros, A., Humphrey, J., Sun, J., Brem, S., et al. (2004). Inhibition of angiogenesis by Abeta peptides. Angiogenesis 7, 75-85. doi: 10.1023/B:AGEN.0000037335.17717.bf
160. Parkin, D. M. (2006). The global health burden of infection-associated cancers in the year 2002. Int. J. Cancer 118, 3030-3044. doi: 10.1002/ijc.21731
161. Patton, R. L., Kalback, W. M., Esh, C. L., Kokjohn, T. A., Van Vickle, G. D., Luehrs, D. C., et al. (2006). Amyloid-β peptide remnants in AN-1792-immunized Alzheimer's disease patients: a biochemical analysis. Am. J. Pathol. 169, 1048-1063. doi: 10.2353/ajpath.2006.060269
162. Penninkilampi, R., Brothers, H. M., and Eslick, G. D. (2016). Pharmacological agents targeting γ-secretase increase risk of cancer and cognitive decline in Alzheimer's disease patients: a systematic review and meta-analysis. J. Alzheimers. Dis. 53, 1395-1404. doi: 10.3233/JAD-160275
163. Penninkilampi, R., Brothers, H. M., and Eslick, G. D. (2017). Safety and efficacy of anti-amyloid-β Immunotherapy in Alzheimer's disease: a systematic review and meta-analysis. J. Neuroimmune Pharmacol. 12, 194-203. doi: 10.1007/s11481-016-9722-5
164. Pfizer (2008). Study Evaluating Bapineuzumab in Alzheimer Disease Subjects
165. Pfizer (2013). A Long-Term Safety and Tolerability Study of Bapineuzumab in Alzheimer Disease Patients
166. Pisa, D., Alonso, R., Juarranz, A., Rábano, A., and Carrasco, L. (2015a). Direct visualization of fungal infection in brains from patients with Alzheimer's disease. J. Alzheimer's Dis. 43, 613-624. doi: 10.3233/JAD-141386
167. Pisa, D., Alonso, R., Rábano, A., Rodal, I., and Carrasco, L. (2015b). Different brain regions are infected with fungi in Alzheimer's disease. Sci. Rep. 5:15015. doi: 10.1038/srep15015
168. Plant, L. D., Boyle, J. P., Smith, I. F., Peers, C., and Pearson, H. A. (2003). The production of amyloid β peptide is a critical requirement for the viability of central neurons. J. Neurosci. 23, 5531-5535. doi: 10.1523/JNEUROSCI.23-13-05531.2003
169. Puig, K. L., and Combs, C. K. (2013). Expression and function of APP and its metabolites outside the central nervous system. Exp. Gerontol. 48, 608-611. doi: 10.1016/j.exger.2012.07.009
170. Purushothuman, S., Marotte, L., Stowe, S., Johnstone, D. M., and Stone, J. (2013). The response of cerebral cortex to haemorrhagic damage: experimental evidence from a penetrating injury model. PLoS ONE 8:e59740. doi: 10.1371/journal.pone.0059740
171. Puzzo, D., and Arancio, O. (2013). Amyloid-β peptide: Dr. Jekyll or Mr. Hyde? J. Alzheimer's Dis. 33 (Suppl. 1), S111-S120. doi: 10.3233/JAD-2012-129033
172. Puzzo, D., Gulisano, W., Arancio, O., and Palmeri, A. (2015). The keystone of Alzheimer pathogenesis might be sought in Aβ physiology. Neuroscience 307, 26-36. doi: 10.1016/j.neuroscience.2015.08.039
173. Puzzo, D., Privitera, L., Fa, M., Staniszewski, A., Hashimoto, G., Aziz, F., et al. (2011). Endogenous amyloid-β is necessary for hippocampal synaptic plasticity and memory. Ann. Neurol. 69, 819-830. doi: 10.1002/ana.22313
174. Ravi, L. B., Mohanty, J. G., Chrest, F. J., Jayakumar, R., Nagababu, E., Usatyuk, P. V., et al. (2004). Influence of beta-amyloid fibrils on the interactions between red blood cells and endothelial cells. Neurol. Res. 26, 579-585. doi: 10.1179/016164104225016227
175. Ricciarelli, R., and Fedele, E. (2017). The amyloid cascade hypothesis in alzheimer's disease: it's time to change our mind. Curr. Neuropharmacol. 15, 926-935. doi: 10.2174/1570159X15666170116143743
176. Rinne, J. O., Brooks, D. J., Rossor, M. N., Fox, N. C., Bullock, R., Klunk, W. E., et al. (2010). 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet. Neurol. 9, 363-372. doi: 10.1016/S1474-4422(10)70043-0
177. Roberts, G. W., Gentleman, S. M., Lynch, A., Murray, L., Landon, M., and Graham, D. I. (1994). Beta amyloid protein deposition in the brain after severe head injury: implications for the pathogenesis of Alzheimer's disease. J. Neurol. Neurosurg. Psychiatr. 57, 419-425. doi: 10.1136/jnnp.57.4.419
178. Robinson, S. R., and Bishop, G. M. (2002). Aβ as a bioflocculant: implications for the amyloid hypothesis of Alzheimer's disease. Neurobiol. Aging 23, 1051-1072. doi: 10.1016/S0197-4580(01)00342-6
179. Robinson, S. R., Bishop, G. M., and Münch, G. (2003). Alzheimer vaccine: amyloid-beta on trial. BioEssays 25, 283-288. doi: 10.1002/bies.10236
180. Robinson, S. R., Bishop, G. M., Lee, H. G., and Münch, G. (2004a). Lessons from the AN 1792 Alzheimer vaccine: lest we forget. Neurobiol. Aging 25, 609-615. doi: 10.1016/j.neurobiolaging.2003.12.020
181. Robinson, S. R., Dobson, C., and Lyons, J. (2004b). Challenges and directions for the pathogen hypothesis of Alzheimer's disease. Neurobiol. Aging 25, 629-637. doi: 10.1016/j.neurobiolaging.2003.12.022
182. Roche (2014). Roche Provides Update on Gantenerumab Development Programme
183. Roe, C. M., Fitzpatrick, A. L., Xiong, C., Sieh, W., Kuller, L., Miller, J. P., et al. (2010). Cancer linked to Alzheimer disease but not vascular dementia. Neurology 74, 106-112. doi: 10.1212/WNL.0b013e3181c91873
184. Roperch, J. P., Alvaro, V., Prieur, S., Tuynder, M., Nemani, M., Lethrosne, F., et al. (1998). Inhibition of presenilin 1 expression is promoted by p53 and p21WAF-1 and results in apoptosis and tumor suppression. Nat. Med. 4, 835-838. doi: 10.1038/nm0798-835
185. Salloway, S., Sperling, R., Gilman, S., Fox, N. C., Blennow, K., Raskind, M., et al. (2009). A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology 73, 2061-2070. doi: 10.1212/WNL.0b013e3181c67808
186. Salloway, S., Sperling, R., Keren, R., Porsteinsson, A. P., van Dyck, C. H., Tariot, P. N., et al. (2011). A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease. Neurology 77, 1253-1262. doi: 10.1212/WNL.0b013e3182309fa5
187. Saumier, D., Duong, A., Haine, D., Garceau, D., and Sampalis, J. (2009). Domain-specific cognitive effects of tramiprosate in patients with mild to moderate Alzheimer's disease: ADAS-cog subscale results from the alphase study. J. Nutr. Health Aging 13, 808-812. doi: 10.1007/s12603-009-0217-4
188. Savage, M. J., Trusko, S. P., Howland, D. S., Pinsker, L. R., Mistretta, S., Reaume, A. G., et al. (1998). Turnover of amyloid beta-protein in mouse brain and acute reduction of its level by phorbol ester. J. Neurosci. 18, 1743-1752. doi: 10.1523/JNEUROSCI.18-05-01743.1998
189. Schneeberger, A., Mandler, M., Otawa, O., Zauner, W., Mattner, F., and Schmidt, W. (2009). Development of AFFITOPE vaccines for Alzheimer's disease (AD)-from concept to clinical testing. J. Nutr. Health Aging 13, 264-267. doi: 10.1007/s12603-009-0070-5
190. Schneider, L. S., Mangialasche, F., Andreasen, N., Feldman, H., Giacobini, E., Jones, R., et al. (2014). Clinical trials and late-stage drug development for Alzheimer's disease: an appraisal from 1984 to 2014. J. Intern. Med. 275, 251-283. doi: 10.1111/joim.12191
191. Schreiber, S., Drukarch, B., Garz, C., Niklass, S., Stanaszek, L., Kropf, S., et al. (2014). Interplay between age, cerebral small vessel disease, parenchymal amyloid-β, and tau pathology: longitudinal studies in hypertensive stroke-prone rats. J. Alzheimer's Dis. 42(Suppl. 3), S205-S215. doi: 10.3233/JAD-132618
192. Scott, G., Ramlackhansingh, A. F., Edison, P., Hellyer, P., Cole, J., Veronese, M., et al. (2016). Amyloid pathology and axonal injury after brain trauma. Neurology 86, 821-828. doi: 10.1212/WNL.0000000000002413
193. Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., et al. (2016). The antibody aducanumab reduces Abeta plaques in Alzheimer's disease. Nature 537, 50-56. doi: 10.1038/nature19323
194. Shi, H.-B., Tang, B., Liu, Y.-W., Wang, X.-F., and Chen, G.-J. (2015). Alzheimer disease and cancer risk: a meta-analysis. J. Cancer Res. Clin. Oncol. 141, 485-494. doi: 10.1007/s00432-014-1773-5
195. Shim, S. M., Cheon, H. S., Jo, C., Koh, Y. H., Song, J., and Jeon, J. P. (2017). Elevated epstein-barr virus antibody level is associated with cognitive decline in the korean elderly. J. Alzheimers. Dis. 55, 293-301. doi: 10.3233/JAD-160563
196. Shishido, H., Kishimoto, Y., Kawai, N., Toyota, Y., Ueno, M., Kubota, T., et al. (2016). Traumatic brain injury accelerates amyloid-β deposition and impairs spatial learning in the triple-transgenic mouse model of Alzheimer's disease. Neurosci. Lett. 629, 62-67. doi: 10.1016/j.neulet.2016.06.066
197. Siemers, E. R., Dean, R. A., Friedrich, S., Ferguson-Sells, L., Gonzales, C., Farlow, M. R., et al. (2007). Safety, tolerability, and effects on plasma and cerebrospinal fluid amyloid-beta after inhibition of gamma-secretase. Clin. Neuropharmacol. 30, 317-325. doi: 10.1097/WNF.0b013e31805b7660
198. Siemers, E. R., Quinn, J. F., Kaye, J., Farlow, M. R., Porsteinsson, A., Tariot, P., et al. (2006). Effects of a gamma-secretase inhibitor in a randomized study of patients with Alzheimer disease. Neurology 66, 602-604. doi: 10.1212/01.WNL.0000198762.41312.E1
199. Sjögren, M., Gisslén, M., Vanmechelen, E., and Blennow, K. (2001). Low cerebrospinal fluid beta-amyloid 42 in patients with acute bacterial meningitis and normalization after treatment. Neurosci. Lett. 314, 33-36. doi: 10.1016/S0304-3940(01)02285-6
200. Soscia, S. J., Kirby, J. E., Washicosky, K. J., Tucker, S. M., Ingelsson, M., Hyman, B., et al. (2010). The Alzheimer's disease-associated amyloid beta-protein is an antimicrobial peptide. PLoS ONE 5:e9505. doi: 10.1371/journal.pone.0009505
201. Sperling, R., Salloway, S., Brooks, D. J., Tampieri, D., Barakos, J., Fox, N. C., et al. (2012). Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis. Lancet. Neurol. 11, 241-249. doi: 10.1016/S1474-4422(12)70015-7
202. Spitzer, P., Condic, M., Herrmann, M., Oberstein, T. J., Scharin-Mehlmann, M., Gilbert, D. F., et al. (2016). Amyloidogenic amyloid-β-peptide variants induce microbial agglutination and exert antimicrobial activity. Sci. Rep. 6:32228. doi: 10.1038/srep32228
203. Steinbach, J. P., Müller, U., Leist, M., Li, Z. W., Nicotera, P., and Aguzzi, A. (1998). Hypersensitivity to seizures in beta-amyloid precursor protein deficient mice. Cell Death Differ. 5, 858-866. doi: 10.1038/sj.cdd.4400391
204. Stone, J. (2008). What initiates the formation of senile plaques? The origin of Alzheimer-like dementias in capillary haemorrhages. Med Hypotheses 71, 347-359. doi: 10.1016/j.mehy.2008.04.007
205. Sudduth, T. L., Weekman, E. M., Brothers, H. M., Braun, K., and Wilcock, D. M. (2014). β-amyloid deposition is shifted to the vasculature and memory impairment is exacerbated when hyperhomocysteinemia is induced in APP/PS1 transgenic mice. Alzheimer's Res. Ther. 6, 32-32. doi: 10.1186/alzrt262
206. Tajiri, N., Kellogg, S. L., Shimizu, T., Arendash, G. W., and Borlongan, C. V. (2013). Traumatic brain injury precipitates cognitive impairment and extracellular Aβ aggregation in Alzheimer's disease transgenic mice. PLoS ONE 8:e78851. doi: 10.1371/journal.pone.0078851
207. Tampellini, D., Rahman, N., Gallo, E. F., Huang, Z., Dumont, M., Capetillo-Zarate, E., et al. (2009). Synaptic activity reduces intraneuronal Abeta, promotes APP transport to synapses, and protects against Abeta-related synaptic alterations. J. Neurosci. 29, 9704-9713. doi: 10.1523/JNEUROSCI.2292-09.2009
208. Tanaka, S., and Nagashima, H. (2017). Establishment of an Alzheimer's disease model with latent herpesvirus infection using PS2 and Tg2576 double transgenic mice. Exp. Anim. doi: 10.1538/expanim.17-0066. [Epub ahead of print]
209. Tarawneh, R., and Holtzman, D. M. (2009). Critical issues for successful immunotherapy in Alzheimer's disease: development of biomarkers and methods for early detection and intervention. CNS Neurol. Disord. Drug Targets 8, 144-159. doi: 10.2174/187152709787847324
210. Tharp, W. G., and Sarkar, I. N. (2013). Origins of amyloid-β. BMC Genomics 14:290. doi: 10.1186/1471-2164-14-290
211. Torres, L., Robinson, S. A., Kim, D. G., Yan, A., Cleland, T. A., and Bynoe, M. S. (2018). Toxoplasma gondii alters NMDAR signaling and induces signs of Alzheimer's disease in wild-type, C57BL/6 mice. J. Neuroinflammation 15:57. doi: 10.1186/s12974-018-1086-8
212. Transition Therapeutics Ireland Limited (2007). ELND005 in Patients With Mild to Moderate Alzheimer's Disease
213. Transition Therapeutics Ireland Limited (2009). [ELND005 Long-Term Follow-up Study in Subjects With Alzheimer's Disease
214. Trapp, B. D., Peterson, J., Ransohoff, R. M., Rudick, R., and Mörk, S., and, B.ö, L. (1998). Axonal transection in the lesions of multiple sclerosis. N. Engl. J. Med. 338, 278-285. doi: 10.1056/NEJM199801293380502
215. Tu, S., Okamoto, S.-I., Lipton, S. A., and Xu, H. (2014). Oligomeric Aβ-induced synaptic dysfunction in Alzheimer's disease. Mol. Neurodegener. 9:48. doi: 10.1186/1750-1326-9-48
216. Vellas, B., Black, R., Thal, L. J., Fox, N. C., Daniels, M., McLennan, G., et al. (2009). Long-term follow-up of patients immunized with AN1792: reduced functional decline in antibody responders. Curr. Alzheimer Res. 6, 144-151. doi: 10.2174/156720509787602852
217. Villar-Piqué, A., Sabaté, R., Lopera, O., Gibert, J., Torne, J. M., Santos, M., et al. (2010). Amyloid-like protein inclusions in tobacco transgenic plants. PLoS ONE 5:e13625. doi: 10.1371/journal.pone.0013625
218. Wang, L., Xi, G., Keep, R. F., and Hua, Y. (2012). Iron enhances the neurotoxicity of amyloid β. Transl. Stroke Res. 3, 107-113. doi: 10.1007/s12975-011-0099-8
219. Washington, P. M., Morffy, N., Parsadanian, M., Zapple, D. N., and Burns, M. P. (2014). Experimental traumatic brain injury induces rapid aggregation and oligomerization of amyloid-β in an Alzheimer's disease mouse model. J. Neurotrauma 31, 125-134. doi: 10.1089/neu.2013.3017
220. White, M. R., Kandel, R., Hsieh, I. N., De Luna, X., and Hartshorn, K. L. (2018). Critical role of the C-terminal residues of the Alzheimer's associated β-amyloid protein in mediating antiviral activity and modulating viral and bacterial interactions with neutrophils. PLoS ONE 13(3):e0194001. doi: 10.1371/journal.pone.0194001
221. White, M. R., Kandel, R., Tripathi, S., Condon, D., Qi, L., Taubenberger, J., et al. (2014). Alzheimer's associated β-amyloid protein inhibits influenza A virus and modulates viral interactions with phagocytes. PLoS ONE 9:e101364. doi: 10.1371/journal.pone.0101364
222. White, R. S., Lipton, R. B., Hall, C. B., and Steinerman, J. R. (2013). Nonmelanoma skin cancer is associated with reduced Alzheimer disease risk. Neurology 80, 1966-1972. doi: 10.1212/WNL.0b013e3182941990
223. Wollenweber, F. A., Buerger, K., Mueller, C., Ertl-Wagner, B., Malik, R., Dichgans, M., et al. (2014). Prevalence of cortical superficial siderosis in patients with cognitive impairment. J. Neurol. 261, 277-282. doi: 10.1007/s00415-013-7181-y
224. Wozniak, M. A., Itzhaki, R. F., Shipley, S. J., and Dobson, C. B. (2007). Herpes simplex virus infection causes cellular beta-amyloid accumulation and secretase upregulation. Neurosci. Lett. 429, 95-100. doi: 10.1016/j.neulet.2007.09.077
225. Wozniak, M. A., Mee, A. P., and Itzhaki, R. F. (2009). Herpes simplex virus type 1 DNA is located within Alzheimer's disease amyloid plaques. J. Pathol. 217, 131-138. doi: 10.1002/path.2449
226. Wu, C.-W., Liao, P.-C., Yu, L., Wang, S.-T., Chen, S.-T., Wu, C.-M., et al. (2004). Hemoglobin promotes Abeta oligomer formation and localizes in neurons and amyloid deposits. Neurobiol. Dis. 17, 367-377. doi: 10.1016/j.nbd.2004.08.014
227. Xiang, Y., Bu, X. L., Liu, Y. H., Zhu, C., Shen, L. L., Jiao, S. S., et al. (2015). Physiological amyloid-beta clearance in the periphery and its therapeutic potential for Alzheimer's disease. Acta Neuropathol. 130, 487-499. doi: 10.1007/s00401-015-1477-1
228. Xu, S., and Gaskin, F. (1997). Increased incidence of anti-beta-amyloid autoantibodies secreted by Epstein-Barr virus transformed B cell lines from patients with Alzheimer's disease. Mech. Ageing Dev. 94, 213-222. doi: 10.1016/S0047-6374(96)01861-1
229. Yarchoan, M., James, B. D., Shah, R. C., Arvanitakis, Z., Wilson, R. S., Schneider, J., et al. (2017). Association of cancer history with Alzheimer's disease dementia and neuropathology. J. Alzheimers. Dis. 56, 699-706. doi: 10.3233/JAD-160977
230. Zhao, H., Zhu, J., Cui, K., Xu, X., O'Brien, M., Wong, K. K., et al. (2009). Bioluminescence imaging reveals inhibition of tumor cell proliferation by Alzheimer's amyloid beta protein. Cancer Cell Int. 9:15. doi: 10.1186/1475-2867-9-15
231. Zunarelli, E., Nicoll, J. A., and Graham, D. I. (1996). Presenilin-1 polymorphism and amyloid beta-protein deposition in fatal head injury. Neuroreport 8, 45-48. doi: 10.1097/00001756-199612200-00010